The most commonly received prescription medications were antidepressants/selective serotonin reuptake inhibitors (SSRIs) and stimulants. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from the Company’s current expectations. We will remove this and make the changes needed. Parents often first recognize the initial symptoms and developmental delays, leading to subsequent clinical diagnosis of FXS utilizing genetic testing for mutations in the FMR1 gene. Prior to that, Ms. Sebree served in a variety of management roles with Abbott Laboratories for more than nine years. The mean age of children with FXS at the time of diagnosis was 36 months. Dr. Palumbo has worked with global regulatory agencies leading to the approval of therapeutics including Radicava® (edaravone), Risperdal® (risperidone), Concerta® (methylphenidate HCL) and Invega® (paliperidone). At NuPathe, she successfully led the effort to develop, achieve regulatory approval, and complete manufacturing of the company’s lead product, Zecuity, the first transdermal patch for migraine. Zygel FXS Development Program Most Recent Joseph M Palumbo, Natalie Silove, Jonathan Cohen, Carol O’Neill, Nancy Tich, Wei Du, Helen Heussler. At NuPathe, she successfully led the intellectual property strategy and the contracts effort in addition to managing the human resources function and she partnered with senior management to complete a successful IPO. By continuing to use this website, you accept our use of these cookies. He most recently served Trevena, Inc. as Vice President, Regulatory Affairs where he led the preparation and submission of the company’s first NDA. (See TCMD stock analysis on TipRanks)uniQure N.V. (QURE)Last but not least we have uniQure, which delivers curative gene therapies that could potentially transform the lives of patients. Devon, PA, May 26, 2020 – Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, is presenting two posters on the safety, efficacy and quality of life results of the Phase 2 BELIEVE (Open Label Study to Assess the Safety and Efficacy of Zygel™ (ZYN002) Administered as a Transdermal Gel to Children and Adolescents with Developmental and Epileptic Encephalopathy) clinical trial.
Jim Fickenscher serves as Zynerba’s Chief Financial Officer, Vice President, Corporate Development. He is an inventor and innovator with multiple patents, and a career that has successfully integrated laboratory science, bedside care and novel medications development. HSBC has declined to comment on the article.“Should it be on the list, even without tough measures taken, its mainland China business would likely be adversely impacted as its clients reduce transactions,” Citigroup analysts led by Yafei Tian wrote in a note on Tuesday.